AHA comments on CMS proposal to codify Medicare Drug Price Negotiation Program regulations
The AHA Aug. 17 provided comments to the Centers for Medicare & Medicaid Services on its proposed rule to codify in regulation the Medicare Drug Price Negotiation Program. The AHA recommended CMS require drug manufacturers to make the maximum fair price available through a point-of-sale mechanism and eliminate any option permitting manufacturers to meet their obligations through retrospective rebates or post-sale reconciliations. The AHA expressed concerns that permitting retrospective MFP ef...
View related coverage on the timeline →
Useful signal?
Sign in with GitHub below to react 👍 / 👎, or comment if a category looks wrong — your reactions help curate this feed. How feedback works
Draft Insight Angle
Auto-generated draft — review and edit before any external use.
Policy / Regulatory Changes signal via AHA News: "AHA comments on CMS proposal to codify Medicare Drug Price Negotiation Program r…".
Analytic angles
- Spans 2 signal categories: Policy / Regulatory Changes, Competitive / Operational Strategy.
- Compare against the current CMS rate/bid-cycle documents.
- Watch for follow-on filings from the named payers.
Draft paragraph
[DRAFT — verify before any external use] AHA News reports on policy / regulatory changes: The AHA Aug. 17 provided comments to the Centers for Medicare & Medicaid Services on its proposed rule to codify in regulation the Medicare Drug Price Negotiation Program. The AHA recommended CMS require drug manufacture…
Note: This is an early signal based on public reporting. Confirm against primary sources before drawing conclusions. Market dynamics may shift as additional information emerges.